TCGA-CQ-6220-01A-11R-1915-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.224885845
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.530
- INTERFERON_GAMMA_RESPONSE+0.410
- MTORC1_SIGNALING+0.390
- PI3K_AKT_MTOR_SIGNALING+0.350
- PROTEIN_SECRETION+0.340
- MYC_TARGETS_V1+0.300
- CHOLESTEROL_HOMEOSTASIS+0.290
- GLYCOLYSIS+0.270
- E2F_TARGETS+0.250
- DNA_REPAIR+0.240
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.340
- ANGIOGENESIS-0.290
- APICAL_SURFACE-0.130
- WNT_BETA_CATENIN_SIGNALING-0.130
- IL2_STAT5_SIGNALING-0.120
- MYOGENESIS-0.120
- PANCREAS_BETA_CELLS-0.080
- NOTCH_SIGNALING-0.070
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-XF-AAN2-01A-11R-A42T-07 | — | — | 0.869 |
| 2 | TCGA-78-7542-01A-21R-2066-07 | — | cohortA1 | 0.839 |
| 3 | X1ce4a106.c532.4678.a6de.8e89f5123c73 | — | cohortMD2 | 0.837 |
| 4 | c340b651-bd01-4194-a67b-e801d0feeb2b | — | — | 0.829 |
| 5 | faffc96a-760c-405c-9bec-d2ec116b4a1d | — | — | 0.828 |
| 6 | TCGA-MT-A51W-01A-21R-A266-07 | — | — | 0.812 |
| 7 | R190 | — | — | 0.808 |
| 8 | TCGA-4Z-AA81-01A-11R-A39I-07 | — | — | 0.806 |
| 9 | R371 | — | — | 0.803 |
| 10 | TCGA-DK-AA77-01A-11R-A39I-07 | — | — | 0.802 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.530 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.410 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.390 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.350 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.340 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.290 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.270 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.250 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.240 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.240 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.240 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.240 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.220 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.210 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.210 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| APOPTOSIS | 0.180 | Idelalisib | — uncovered |